20th Mar 2025 14:31
Hutchmed China Ltd - Hong Kong-based biopharmaceutical firm - Results from the Savannah phase 2 trial showed savolitinib plus Tagrisso achieved a clinically meaningful and durable objective response rate in patients with epidermal growth factor receptor mutated non-small cell lung cancer with high levels of MET overexpression and/or amplification, whose disease progressed on treatment with first line Tagrisso. MET refers to abnormal production of a receptor tyrosine kinase, beyond its normal levels, and is associated with tumour growth and progression. Hutchmed will present new and updated data from several studies in Paris at the European Lung Cancer Congress, which will take place between next week Wednesday and March 29. Tagrisso is a drug made by AstraZeneca PLC. Read More
